ArticleOncogene2010
Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1.
Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026Review
- Knockout of kdm4aa inhibits early embryonic development in zebrafish via downregulating cyp26a1.Molecular genetics and genomics : MGG · 2026Article
- Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.Genes and immunity · 2025Article
- Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.Biomedicines · 2023Review
- Elevated expression of endocan in the development of cervical squamous neoplasia of the uterus.Medical molecular morphology · 2023Article
- Retinoic acid metabolism in cancer: potential feasibility of retinoic acid metabolism blocking therapy.Medical molecular morphology · 2023Review
- Enhancement of Efficacy of Retinoids through Enhancing Retinoid-Induced RAR Activity and Inhibiting Hydroxylation of Retinoic Acid, and Its Clinical Efficacy on Photo-Aging.Pharmaceutics · 2022Article
- Article
- Mitonuclear mismatch alters nuclear gene expression in naturally introgressed Rhinolophus bats.Frontiers in zoology · 2021Article
- CYP2C9 inhibits the invasion and migration of esophageal squamous cell carcinoma via downregulation of HDAC.Molecular and cellular biochemistry · 2021Article
- Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.Biomedicines · 2021Review
- CYP26A1 Is a Novel Biomarker for Betel Quid-Related Oral and Pharyngeal Cancers.Diagnostics (Basel, Switzerland) · 2020Article
- Retinoic Acids in the Treatment of Most Lethal Solid Cancers.Journal of clinical medicine · 2020Review
- Review
- Genetics of Human Longevity From Incomplete Data: New Findings From the Long Life Family Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2018Article
- Retinoic acid-metabolizing enzyme cytochrome P450 26A1 promotes skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene.Oncology letters · 2018Article
- Cancer Stem Cells: Emergent Nature of Tumor Emergency.Frontiers in genetics · 2018Article
- Identification of compounds that modulate retinol signaling using a cell-based qHTS assay.Toxicology in vitro : an international journal published in association with BIBRA · 2016Article
- Elevated expression of the retinoic acid-metabolizing enzyme CYP26C1 in primary breast carcinomas.Medical molecular morphology · 2016Article
- Retinoids and rexinoids in cancer prevention: from laboratory to clinic.Seminars in oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis in animal models and elevated risk for a number of human cancers. Here, we found that CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, is highly expressed in 42% (27/65) of primary breast cancers. We also showed that enhanced expression of CYP26A1 suppresses cellular responses to anoikis and consequently promotes anchorage-independent growth. This transformed phenotype was sufficient to markedly increase tumorigenic and metastatic potential. Suppression of CYP26A1 significantly reversed the CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular RA status and tumorigenicity. Our observations provide strong evidence for oncogenic and cell survival properties of CYP26A1 in carcinogenesis, and suggest mechanisms whereby VAD might promote cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.